Roche (RHHBY) announced positive phase I/II data on NXT007 in people with haemophilia A, supporting its progression into phase III clinical development. NXT007 is a next-generation investigational bispecific antibody, engineered by Chugai, a member of the Roche Group. Early data from the NXTAGE study suggest that NXT007 may have the potential to provide haemostatic normalization in people with haemophilia A. NXT007 showed a tolerable safety profile with no thromboembolic events reported so far. These results were featured as an oral presentation at the 2025 International Society on Thrombosis and Haemostasis, ISTH, Congress, 21-25 June, Washington D.C., United States. NXT007 will be further evaluated in a clinical development program, including ongoing phase I/II clinical trials, with additional phase II data expected later this year. There are also three phase III studies currently planned for 2026
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RHHBY:
- Roche says Lunsumio-Polivy combo significantly prolongs remission in study
- Genentech reports 11.5 months progression-free survival in SUNMO study
- Sarepta Stock (SRPT) Could Soar 200% Despite Growing Caution on Wall Street
- MAIA Biotechnology, Roche sign supply agreement for cancer therapies
- Trump administration weighs crackdown on pharma ads, Bloomberg says
Looking for a trading platform? Check out TipRanks' Best Online Brokers guide, and find the ideal broker for your trades.
Report an Issue